

**U.S. NUCLEAR REGULATORY COMMISSION**

Date: 10/12/06

**TELEPHONE CONVERSATION RECORD**

Time: 1:45 PM

Mail Control	139501	License No(s).	29-00170-03	Docket No(s).	03005224
or Report No(s).	139502		29-00170-08		03036894
	139503		SMB-1260		04008478

Name of Licensee: Bell Laboratories  
A Division of Lucent Technologies, Inc.

Name of Participant(s): Richard Quick, EH&S Senior Manager and RSO  
John Riley, Radiation Safety Consultant

Telephone No. 908-582-5907

Subject: RAI, Determine Action Plan

(NOTE: This will be used as the  
Documents Title in ADAMS)

Summary:

The letter dated September 29, 2006 has two possible requests. I discussed in order to follow option A and reduce the amount of financial assurance, that they need to send in an updated Decommissioning Funding Plan as described in NUREG-1757 along with a Certification of Financial Assurance. They would still need to pursue option B afterwards to remove all financial assurance requirements. Additionally, financial assurance documents will need to be updated with the expected name change.

In order to pursue option B, they should amend the 29-00170-08 license to include the Tracerlab sources so that all materials are under one license. The amount of sealed sources based on the current amount of material (as stated in the phone call) would allow them to remove financial assurance requirements from that license. Then they should proceed to terminate the 29-00170-03 and SMB-1260 licenses. Once those licenses are terminated and the 29-00170-08 license does not require financial assurance, then the financial instruments could be returned.

The licensee determined that they would leave the financial instrument currently in place and pursue option B. I stated that the Decommissioning Funding Plan is required to be updated every 3 years and that it must be available for inspection, however it did not need to be sent to us except during renewal. They stated it was updated and is available for inspection.

The licensee concurred with voiding this action as nothing needs to be performed associated with financial assurance since they are pursuing option B.

Action Required:

Void these licensing actions.

Document Availability:

Publicly Available

Non-Publicly Available

Non-Sensitive

Non-Sensitive Copyright

Sensitive

Sensitive Copyright

Immediate Release

Normal Release

Delay Release Date

Prepared & SUNSI Review Completed By: Dennis Lawyer

/ RA /

Date: 10/12/06